Adaptaquin
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561218

CAS#: 385786-48-1

Description: Adaptaquin is a hydroxyquinoline inhibitor of HIF-PHD enzymes. Adaptaquin reduces neuronal death and behavioral deficits after intracerebral hemorrhage (ICH) in several rodent models without affecting total iron or zinc distribution in the brain.


Price and Availability

Size
Price

5mg
USD 210
Size
Price

10mg
USD 350
Size
Price

50mg
USD 890

Adaptaquin, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 561218
Name: Adaptaquin
CAS#: 385786-48-1
Chemical Formula: C21H16ClN3O2
Exact Mass: 377.0931
Molecular Weight: 377.83
Elemental Analysis: C, 66.76; H, 4.27; Cl, 9.38; N, 11.12; O, 8.47


Synonym: Adaptaquin

IUPAC/Chemical Name: 7-[(4-Chlorophenyl)[(3-hydroxy-2-pyridinyl)amino]methyl]-8-quinolinol

InChi Key: KKYHNYRUBSYTCZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H16ClN3O2/c22-15-8-5-14(6-9-15)18(25-21-17(26)4-2-12-24-21)16-10-7-13-3-1-11-23-19(13)20(16)27/h1-12,18,26-27H,(H,24,25)

SMILES Code: OC1=C2N=CC=CC2=CC=C1C(C3=CC=C(Cl)C=C3)NC4=NC=CC=C4O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Karuppagounder SS, Alim I, Khim SJ, Bourassa MW, Sleiman SF, John R, Thinnes CC, Yeh TL, Demetriades M, Neitemeier S, Cruz D, Gazaryan I, Killilea DW, Morgenstern L, Xi G, Keep RF, Schallert T, Tappero RV, Zhong J, Cho S, Maxfield FR, Holman TR, Culmsee C, Fong GH, Su Y, Ming GL, Song H, Cave JW, Schofield CJ, Colbourne F, Coppola G, Ratan RR. Therapeutic targeting of oxygen-sensing prolyl hydroxylases abrogates ATF4-dependent neuronal death and improves outcomes after brain hemorrhage in several rodent models. Sci Transl Med. 2016 Mar 2;8(328):328ra29. doi: 10.1126/scitranslmed.aac6008. PubMed PMID: 26936506; PubMed Central PMCID: PMC5341138.

2: Neitemeier S, Dolga AM, Honrath B, Karuppagounder SS, Alim I, Ratan RR, Culmsee C. Inhibition of HIF-prolyl-4-hydroxylases prevents mitochondrial impairment and cell death in a model of neuronal oxytosis. Cell Death Dis. 2016 May 5;7:e2214. doi: 10.1038/cddis.2016.107. PubMed PMID: 27148687; PubMed Central PMCID: PMC4917646.